An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia.

Trial Profile

An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs ACT-GRO-777 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2011 Status changed from recruiting to discontinued, according to an Antisoma media release.
    • 01 Feb 2011 Additional location [Taiwan] identified as reported by ClinicalTrials.gov.
    • 13 Oct 2010 Results are expected in the first half of 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top